- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
A GP said Bydureon prescribing information was “incredibly difficult to read”. Panel found it was near the limit…
A doctor challenged a third‑party invitation to a paid “training day research” workshop for rep mock consultations. Panel…
MSD challenged a Victoza detail aid using a composite endpoint. Panel found the prominent red “HbA1c<7% + weight…
Bayer sponsored a BJMA UK meeting in Bolton (July 2013) with a stand and speaker. Panel found the…
A PV associate following up a Yellow Card report asked a pharmacy for patient contact details and DOB…
Bayer challenged Lixiana leavepiece claims. Panel found breaches where VTE “initiation” wording obscured heparin lead-in and where a…
Anonymous oncologist alleged overly frequent contact, unannounced clinic visits, old data and failure to leave copies. Panel found…
A Cymbalta detail aid implied duloxetine and venlafaxine XL had equivalent efficacy based on a single head-to-head study.…
Amgen admitted Aranesp (POM) branded materials were briefly displayed at a National Kidney Foundation conference accessible to patients/public.…
Complaint about clinical trial disclosure for ellaOne. PMCPA found the matter was outwith the scope of the ABPI…
One real case. One key lesson. Every week — free.